

20 Sep 2019 | News

QUOTED. 20 September 2019. Eran Atlas.

by

Tel-Aviv, Israel-based DreaMed Diabetes received another US Food and Drug Administration clearance for its AI-powered Advisor Pro software, which helps providers manage and optimize treatment for patients with type 1 diabetes. See what DreaMed's CEO, Eran Atlas, said about it here.

"What we have right now with our technology is the ability to provide recommendations for the entire insulin pump type 1 population, so we are more than doubling the market potential for our business." – Eran Atlas, CEO, DreaMed Diabetes

- Find out more: [DreaMed Receives Another FDA Clearance For AI-Powered Diabetes Software](#)

[Click here](#) for a free trial of *Medtech Insight*